Syros Pharmaceuticals Inc SYRS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRS
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRS
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRS
-
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
-
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRS
-
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged
-
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
Trading Information
- Previous Close Price
- $1.94
- Day Range
- $1.95–2.00
- 52-Week Range
- $1.43–8.17
- Bid/Ask
- $1.94 / $1.98
- Market Cap
- $52.55 Mil
- Volume/Avg
- 77,863 / 317,809
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 16.04
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 68
- Website
- https://www.syros.com
Comparables
Valuation
|
Metric
|
SYRS
|
ACLX
|
IMVT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 8.61 | 8.19 |
Price/Sales | 16.04 | 27.51 | — |
Price/Cash Flow | — | 507.02 | — |
Price/Earnings
SYRS
ACLX
IMVT
Financial Strength
|
Metric
|
SYRS
|
ACLX
|
IMVT
|
|---|---|---|---|
Quick Ratio | 3.22 | 5.85 | 12.49 |
Current Ratio | 3.46 | 6.01 | 13.08 |
Interest Coverage | −24.77 | −28.35 | — |
Quick Ratio
SYRS
ACLX
IMVT
Profitability
|
Metric
|
SYRS
|
ACLX
|
IMVT
|
|---|---|---|---|
Return on Assets (Normalized) | −73.48% | −1.88% | −45.56% |
Return on Equity (Normalized) | −402.19% | −3.31% | −49.69% |
Return on Invested Capital (Normalized) | −122.29% | −7.10% | −54.28% |
Return on Assets
SYRS
ACLX
IMVT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Dtdxwsngkk | Hywc | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Hhmwzccfc | Jlksdq | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Qnvxcqbw | Qpcqv | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Kdstrphr | Mblmlh | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Xcqqlvd | Qhhvr | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Qdnyvsrb | Kzvcy | $29.2 Bil | |||
| Moderna Inc
MRNA
| Wclchdlwn | Xzbl | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Tdygzqmf | Dhhnr | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Vdyrcrdll | Jbysrt | $13.2 Bil | |||
| Incyte Corp
INCY
| Ftymnmnq | Lxqmwb | $13.0 Bil |
United States